Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy

Group 1 - Contrarius Global Equity Fund achieved a return of 30.9% in the September quarter, significantly outperforming the benchmark MSCI World Index which returned 7.3% and the Average Global Equity Fund at 5.5% [1] - The fund's investment strategy is independent of benchmark considerations, leading to portfolios that typically deviate from the benchmark World Index [1] - The fund's investor letter highlights its top five holdings, indicating its leading picks for 2025 [1] Group 2 - CRISPR Therapeutics AG (NASDAQ:CRSP) is a key stock highlighted by the Contrarius Global Equity Fund, specializing in gene-based medicines for serious human diseases [2] - CRISPR Therapeutics AG experienced a one-month return of 4.63% and a 52-week gain of 37.12%, with its stock closing at $53.97 per share on December 29, 2025, and a market capitalization of $5.143 billion [2] - The FDA approved the first CRISPR-Cas9 gene editing therapy for sickle cell disease in December 2023, after nearly six years of human clinical trials, marking a significant milestone for CRISPR Therapeutics AG [3]